Latanoprost derivatives show help for glaucoma

Sophia Antipolis, France-Nitric oxide-donating derivatives of latanoprost (Xalatan) are showing an improved ability to lower IOP for the treatment of glaucoma, according to preclinical results of research conducted by NicOx SA and Pfizer Inc.

Sophia Antipolis, France-Nitric oxide-donating derivatives of latanoprost (Xalatan) are showing an improved ability to lower IOP for the treatment of glaucoma, according to preclinical results of research conducted by NicOx SA and Pfizer Inc.

The derivative compound was able to reduce IOP significantly in animals with glaucoma. The compound was developed through a 2004 collaboration agreement between the two companies. Results were presented during the Association for Ocular Pharmacology and Therapeutics eighth scientific meeting in San Diego.

In one model, a single topical 0.1% dose of latanoprost resulted in an 18% maximal reduction of IOP compared with a 30% reduction achieved with an equimolar dose of the presented compound.

In March 2006, the companies signed a second agreement giving Pfizer exclusive rights to apply NicOx' proprietary nitric oxide-donating technology across all of ophthalmology.